Yani Zhang, Zheng Yang, Ting Xu, Qian Wang, Tingting Sang, Xuan Sheng, Yan Fang, Lisheng Chu
{"title":"5-Lipoxygenase triggers depressive-like behaviors via activating NLRP3-induced pyroptosis in CUMS-exposed mice.","authors":"Yani Zhang, Zheng Yang, Ting Xu, Qian Wang, Tingting Sang, Xuan Sheng, Yan Fang, Lisheng Chu","doi":"10.1016/j.neuropharm.2025.110704","DOIUrl":null,"url":null,"abstract":"<p><p>5-Lipoxygenase (5-LOX) is implicated the pathogenesis of depression, yet the underlying molecular mechanism remains unclear. In our study, we investigated the dynamic changes of 5-LOX expression after chronic unpredictable mild stress (CUMS) stimulation. The results demonstrated that 5-LOX expression was significantly upregulated in the prefrontal cortex (PFC) after CUMS stimulation for 2 weeks, 4 weeks and 8 weeks. CUMS stimulation activated 5-LOX on neurons, and induced neuronal loss in the PFC. Moreover, the expression levels of pyroptosis-related proteins showed a gradual increase with prolongation of CUMS stimulation. Notably, inhibiting 5-LOX with zileuton effectively alleviated depressive-like behaviors, increased the expression of monoamine neurotransmitters and exerted neuroprotective effects in CUMS-exposed mice. 5-LOX inhibition also markedly reduced the expression levels of pyroptosis-related proteins. We further explored the role of 5-LOX in NLRP3-mediated cell pyroptosis in vitro. 5-LOX knockdown significantly suppressed LPS/ATP-induced pyroptosis in PC12 cells. 5-LOX overexpression enhanced the pyroptosis induced by LPS/ATP, while NLRP3 inhibitors reversed the aggravation. These findings indicate that 5-LOX contributes to the pathogenesis of depression via promoting NLRP3-mediated cell pyroptosis. Thus, 5-LOX inhibition could be applied as a clinic intervention for the treatment of depression.</p>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":" ","pages":"110704"},"PeriodicalIF":4.6000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.neuropharm.2025.110704","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
5-Lipoxygenase (5-LOX) is implicated the pathogenesis of depression, yet the underlying molecular mechanism remains unclear. In our study, we investigated the dynamic changes of 5-LOX expression after chronic unpredictable mild stress (CUMS) stimulation. The results demonstrated that 5-LOX expression was significantly upregulated in the prefrontal cortex (PFC) after CUMS stimulation for 2 weeks, 4 weeks and 8 weeks. CUMS stimulation activated 5-LOX on neurons, and induced neuronal loss in the PFC. Moreover, the expression levels of pyroptosis-related proteins showed a gradual increase with prolongation of CUMS stimulation. Notably, inhibiting 5-LOX with zileuton effectively alleviated depressive-like behaviors, increased the expression of monoamine neurotransmitters and exerted neuroprotective effects in CUMS-exposed mice. 5-LOX inhibition also markedly reduced the expression levels of pyroptosis-related proteins. We further explored the role of 5-LOX in NLRP3-mediated cell pyroptosis in vitro. 5-LOX knockdown significantly suppressed LPS/ATP-induced pyroptosis in PC12 cells. 5-LOX overexpression enhanced the pyroptosis induced by LPS/ATP, while NLRP3 inhibitors reversed the aggravation. These findings indicate that 5-LOX contributes to the pathogenesis of depression via promoting NLRP3-mediated cell pyroptosis. Thus, 5-LOX inhibition could be applied as a clinic intervention for the treatment of depression.
期刊介绍:
Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).